In Q3 2025, Surmodics generated $29.6 million in revenue, with a GAAP diluted EPS of -$0.37 and a Non-GAAP diluted EPS of $0.06. Net loss was $5.3 million, operating loss was $5.2 million, and Adjusted EBITDA reached $3.43 million. The company maintained stable revenue excluding SurVeil DCB license fees and saw strong growth in its Pounce Thrombectomy Platform.

Surmodics reported a total revenue of $28.1 million for the second quarter of fiscal year 2025, a 12% decrease year-over-year. The company experienced a GAAP net loss of $(5.2) million, compared to a net income of $0.2 million in the prior-year period. Adjusted EBITDA was $1.9 million, down from $4.8 million.

Surmodics reported a slight decrease in total revenue, a net loss, and an adjusted EBITDA that was slightly less than the prior year. The revenue decrease was primarily due to lower SurVeil DCB revenue, offset by growth in other areas. The net loss was impacted by merger-related charges.

Surmodics reported a 19% year-over-year increase in total revenue for Q4 2024, driven by strong performance in the Medical Device segment. The company's GAAP net loss was $(3.4) million, while adjusted EBITDA reached $4.4 million.

Surmodics reported a decrease in total revenue, primarily due to a significant drop in license fee revenue from the SurVeil DCB. However, excluding this license fee revenue, total revenue increased by 10%. The company experienced a GAAP net loss compared to a net income in the prior-year period, and operating costs increased due to merger-related charges.

Surmodics reported an 18% increase in total revenue to $32.0 million for the second quarter of fiscal year 2024, with net income of $0.2 million. The company also announced the commercial launch of two new thrombectomy devices, Pounce™ Venous and Pounce LP. Updated financial guidance for fiscal year 2024 reflects increased revenue and EPS expectations.

Surmodics reported a 23% increase in total revenue to $30.6 million for Q1 2024. The company saw a GAAP net loss of $(0.8) million and an Adjusted EBITDA of $3.9 million. They have updated their fiscal year 2024 financial guidance to reflect this performance.

Surmodics reported an 8% increase in total revenue to $28.0 million for the fourth quarter of fiscal year 2023, with GAAP EPS of $0.47 and non-GAAP EPS of $0.53. The company's revenue performance exceeded its guidance range, driven by contributions from both business segments. Surmodics is strategically positioned for future success with a portfolio of key product growth catalysts and a healthy balance sheet.

Surmodics reported a significant increase in revenue, driven by a milestone payment related to FDA approval of SurVeil DCB and strong performance in the Medical Device segment. The company also saw improvements in profitability and updated its financial guidance for fiscal year 2023.

Surmodics reported a 4% year-over-year increase in total revenue, reaching $27.2 million. The Medical Device segment saw a 7% increase, driven by vascular intervention products. GAAP diluted EPS was $(0.55), and non-GAAP diluted EPS was $(0.40). The company updated its fiscal year 2023 financial guidance, expecting total revenue to range from $103 million to $106 million.

Surmodics reported an 8% increase in total revenue to $24.9 million for the first quarter of fiscal year 2023. The company experienced a GAAP diluted EPS of $(0.56) and a non-GAAP diluted EPS of $(0.50). Surmodics updated its financial guidance for fiscal year 2023, expecting total revenue to range from $102 million to $106 million.

Surmodics reported an 8% increase in total revenue for the fourth quarter of fiscal year 2022, driven by growth in Medical Device revenue. Progress was made on strategic objectives, including the submission of a complete response to FDA comments for the SurVeil drug-coated balloon.

Surmodics reported solid financial results for Q3 2022, with revenue of $24.9 million, a 4% increase year-over-year. The company delivered double-digit product sales growth for the fourth consecutive quarter and is making meaningful investments in growth initiatives. However, the company reported a GAAP EPS loss of $(0.41) and a non-GAAP EPS loss of $(0.34).

Surmodics, Inc. announced its fiscal year 2022 second quarter results, which included a revenue of $26.1 million, a sequential increase of 13%, and record In Vitro Diagnostics revenue of $7.7 million. The company's GAAP EPS was $(0.29), and its non-GAAP EPS was $(0.22).

Surmodics, Inc. announced its first quarter fiscal 2022 results, showing a 3% increase in revenue compared to the prior-year period. The company's GAAP EPS was $(0.20), while non-GAAP EPS was $(0.13). Surmodics also saw the first commercial sale of its Pounce™ Arterial Thrombo-embolectomy System.

Surmodics, Inc. reported its fourth quarter fiscal 2021 results, with revenue increasing by 6% year-over-year. The company's GAAP EPS was $(0.02), and non-GAAP EPS was $(0.10). The company also issued fiscal 2022 revenue and EPS guidance.

Surmodics reported a decrease in revenue for Q3 2021, with a net loss incurred during the quarter. The company experienced lower sales in both its Medical Device and In Vitro Diagnostics segments.

Surmodics reported a strong second quarter, with revenue of $35.0 million, a 53% increase year-over-year. GAAP EPS was $0.58 and non-GAAP EPS was $0.62. The company recognized $10.8 million in license fee revenue from the SurVeil™ Development and Distribution Agreement with Abbott.

Surmodics reported a slight decrease in revenue for the first quarter of fiscal year 2021, with total revenue at $22.3 million compared to $22.6 million in the prior-year period. The company experienced a GAAP loss per share of ($0.02), while non-GAAP EPS was $0.02. Surmodics also achieved a $15 million milestone related to the TRANSCEND clinical report under the SurVeil Development and Distribution Agreement with Abbott Vascular.

Surmodics reported a decrease in revenue for the fourth quarter of fiscal year 2020, with a GAAP loss per share. The company received FDA clearance for its PounceTM Thrombus Retrieval System.

Surmodics reported a revenue increase of 10% year-over-year, with GAAP EPS at $0.18 and non-GAAP EPS at $0.21. The company achieved critical milestones with CE Mark for SurVeil DCB and FDA clearance for Sublime PTA balloon catheter.

Surmodics, Inc. reported a slight increase in revenue for the second quarter of fiscal year 2020, with a 1% increase year-over-year. GAAP EPS was $0.11, while non-GAAP EPS was $0.04. The company has suspended its financial guidance for fiscal year 2020 due to the uncertainty surrounding the COVID-19 pandemic.

Surmodics reported a 2% increase in revenue for the first quarter of fiscal year 2020, reaching $22.6 million. GAAP EPS was $0.01, and non-GAAP EPS was $0.05. A partnership with Medtronic was announced for the distribution of the TelemarkTM coronary support catheter.